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We report results on risk factors for invasive squamous cell and adenocarcinomas of the cervix in women aged 20–44 years from the
UK National Case–Control Study of Cervical Cancer, including 180 women with adenocarcinoma, 391 women with squamous cell
carcinoma and 923 population controls. The risk of both squamous cell and adenocarcinoma was strongly related to the lifetime
number of sexual partners, and, independently, to age at first intercourse. The risk of both types of cervical cancer increased with
increasing duration of use of oral contraceptives, and this effect was most marked in current and recent users of oral contraceptives.
The risk of squamous cell carcinoma was associated with high parity and the risk of both squamous cell and adenocarcinoma
increased with early age at first birth. Long duration smoking (20 or more years) was associated with a two-fold increase in the risk of
squamous cell carcinoma, but smoking was not associated with the risk of adenocarcinoma. Further studies are needed to confirm the
suggestion from this and other studies of differences in risk related to smoking between squamous cell and adenocarcinomas of the
cervix.
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Among cancers of the uterine cervix, adenocarcinomas are much
less common than squamous cell carcinomas. As for squamous cell
carcinoma, human papillomavirus (HPV) infection appears to be a
major risk factor for adenocarcinoma of the cervix (Kjaer and
Brinton, 1993; Walboomers et al, 1999; Santos et al, 2001;
Altekruse et al, 2003), but evidence on other factors that may
affect the risk of adenocarcinoma is limited and not entirely
consistent (Parazzini and La Vecchia, 1990; Kjaer and Brinton,
1993; Ursin et al, 1994, 1996; Lacey et al, 1999, 2000, 2001;
Madeleine et al, 2001; Altekruse et al, 2003). The question of
whether there are substantial differences in the risk factors for
adenocarcinomas and squamous cell carcinomas remains unre-
solved. Few epidemiological studies have been designed specifi-
cally to provide a direct comparison between adenocarcinoma and
squamous cell carcinoma of the cervix, and most studies of cervical
carcinoma have had too few cases of adenocarcinoma to allow full
evaluation of the possible risk factors. We present here results
from the UK National Case–Control Study of Cervical Cancer, a
case–control study of risk factors for invasive cervical cancer in
women under 45 years old at diagnosis, with 180 cases of
adenocarcinoma (including adenosquamous carcinoma), 391 cases
of squamous cell carcinoma and 923 population controls.
Information was available for all study subjects on sexual and
reproductive factors, cervical screening, body weight, smoking and
the use of barrier and hormonal contraceptives. Additional
information was collected on HPV serology for a subgroup of
subjects, and for this subgroup results have previously been
published on the relationship between HPV positivity and risk of
cervical cancer (Jha et al, 1993), and on oral contraceptive use as a
risk factor for cervical cancer in relation to HPV positivity
(Berrington et al, 2002).
METHODS
Recruitment took place between 1987 and 1989. Cases were white
women with biopsy-confirmed invasive cervical cancer diagnosed
at age 20–44 years in the UK between 1984 and 1988, selected from
five UK Cancer Registries (South Thames, Oxfordshire, Lothian,
North Western and Yorkshire), with additional cases from hospital
treatment centres. Squamous cell and adenocarcinoma cases were
frequency matched by age group; the mean (and median) age of
squamous cell carcinoma cases was 33 years and of adenocarci-
noma cases was 35 years. For each woman with cervical cancer,
between one and three control women matched for age (within 12 Received 14 July 2003; revised 30 July 2003; accepted 6 August 2003
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ymonths) were selected from the patient lists of the case’s general
practitioner. Women were excluded from the study if they had
prior malignancy (other than squamous cell and basal call
carcinoma of the skin and intraductal breast cancer), severe
mental handicap or mental illness, insufficient knowledge of the
English language, were a member of the Armed Services or
were born outside Europe, Africa, Australasia or North America.
Cases and controls were interviewed at home by a trained nurse
interviewer. A structured questionnaire was used to obtain
information on occupation, past medical history, smoking and
sexual and reproductive factors, including use of barrier and oral
contraceptives and history of screening for cervical cancer.
Information on obstetric history and prescriptions for oral
contraceptives was obtained from the notes of the general
practitioner and, if relevant, the family planning clinic. Results
of cervical smear tests were confirmed through the cervical
screening service. A total of 181 women with adenocarcinoma or
adenosquamous carcinoma and three matched controls per case
(538 in total), and 397 women with squamous cell carcinoma, each
with one matched control, were recruited. For analysis, subjects
who were virgins and those with unknown values for any of the
adjustment variables were excluded; final analyses were based on
180 cases of adenocarcinoma and their 532 matched controls, and
391 matched pairs of squamous cell carcinoma cases and controls.
In order to increase the stability of risk estimates, and to provide
a better comparison between the two histological types, the
matching was broken and analyses were performed using a single,
pooled, group of controls. Odds ratios (ORs) and 95% confidence
intervals (CIs) for the variables of interest were calculated
separately for adenocarcinoma and for squamous cell carcinoma
compared with controls, and for squamous cell carcinoma cases
compared with adenocarcinoma cases, using unconditional multi-
ple logistic regression. Tests for linear trends were obtained by
using the midpoint values of each category and treating this scored
variable as continuous. Potential confounders were investigated
and the following were adjusted for, as appropriate, in all models:
age (5-year age groups; finer stratification by age did not
materially alter the results), recruitment centre, age at first
intercourse, duration of oral contraceptive use, level of education,
number of negative screening results, smoking status and total
number of sexual partners.
RESULTS
Sexual behaviour
For both squamous cell carcinoma and adenocarcinoma, the risk
of cervical cancer increased with increasing lifetime number of
sexual partners (Table 1). The effect was somewhat stronger for
squamous cell carcinoma, with an odds ratio of 4.09 (95% CI
(2.75–6.08) for women reporting five or more partners compared
to those with one partner. There was a highly significant trend in
risk (P¼o0.0001). The equivalent odds ratio for adenocarcinoma
was 1.98 (1.21–3.26), and there was no significant trend (P¼0.1).
For both types of cervical cancer, the association with sexual
partners was seen only for regular (relationship lasting more than
3 months) and not for non-regular partners. Odd ratios for cervical
cancer in women with three or more regular partners compared
with women with one or no regular partners were 3.40 (2.38–4.86)
for squamous cell carcinoma and 2.18 (1.36–3.47) for adenocarci-
noma. Direct comparison showed a higher risk of marginal
statistical significance for squamous cell compared with adeno-
carcinoma for five or more total partners (OR¼1.78 (1.00–3.18))
and for three or more regular partners (OR¼1.63 (0.97–2.71)).
Owing to the small numbers of adenocarcinoma cases in the upper
categories for number of partners, these results are given for three
categories only; finer stratification by number of partners within
the upper category for lifetime or regular partners did not
substantially alter the results.
The risk of cervical cancer was higher for earlier age at first
intercourse for both squamous cell (P for trend p0.0001) and
adenocarcinoma (P¼0.004). Women with an age at first
intercourse of 17 years or less had a 2–3-fold higher risk of
cancer than those with first intercourse at 20 years or older. Direct
comparison showed no significant difference between squamous
cell and adenocarcinoma cases.
Weight and body mass index
No relationship was seen between either self-reported weight or
body mass index (1 year before diagnosis or pseudodiagnosis) and
the risk of squamous cell or adenocarcinoma of the cervix
(Table 1).
Reproductive factors
Of 391 women with squamous cell carcinoma, 350 had been
pregnant, of whom 331 reported one or more live births, six
reported one or two stillbirths and 152 reported one or more
interrupted pregnancies (termination of pregnancy or spontaneous
miscarriage). For 180 women with adenocarcinoma, the equivalent
numbers were 163 ever pregnant, 159 reporting one or more live
births, two reporting stillbirth and 54 reporting interrupted
pregnancy. Table 2 shows odds ratios for the risk of adenocarci-
noma and squamous cell carcinoma in relation to several
reproductive factors. No statistically significant associations were
seen between the risk of squamous cell or adenocarcinoma and
ever having given birth, time since last birth or number of
interrupted pregnancies. For squamous cell carcinoma only there
was a statistically significant increase in risk associated with
increasing number of live births (OR¼1.86 (1.16–2.99) for three
or more live births compared with no live births; P trend¼0.001).
For adenocarcinoma, the odds ratio for three or more live births
was 1.44 (0.76–2.73), with no significant trend (P¼0.3). Both
squamous cell and adenocarcinoma showed an increased risk with
early age at first birth, with women with age at first birth of 15–19
years having a risk of cervical cancer about twice that of women
whose first birth was at 25 years or older. On direct comparison,
there were no statistically significant differences between squa-
mous cell carcinoma and adenocarcinoma cases in relation to
reproductive factors.
Oral contraceptives
Use of oral contraceptives was associated with an increased risk of
cervical cancer (Table 3). This association was seen for both
squamous cell and adenocarcinoma. For squamous cell carcinoma,
ever use of oral contraceptives was associated with a marginally
significant increase in risk (OR¼1.37 (0.97–1.94)), with a similar
increase seen in past (OR¼1.31 (0.92 –1.87)) and current users
(OR¼1.64 (1.06–2.55)); for adenocarcinoma, risk was signifi-
cantly increased in ever users (OR¼1.56 (1.01–2.42) and in
current, but not in past, users ( OR for current users¼2.36 (1.34–
4.16)). For both types of cancer, there was a clear relationship
between cancer risk and duration of use of oral contraceptives,
with highly significant trends of increasing risk with increasing
duration of use (P trend¼0.001 for adenocarcinoma and o0.0001
for squamous cell carcinoma). Compared with never use (includ-
ing use for less than a year), odds ratios for 10 or more years of use
were 1.89 (1.22–2.93) for squamous cell carcinoma and 2.06
(1.19–3.57) for adenocarcinoma. Risk was also related to time
since last use of oral contraceptives, with higher risk for more
recent use. When duration of use was considered in relation to
time since last use, a significant increase in cancer risk with
increased duration of use of oral contraceptives was seen only in
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had used combined oral contraceptives, and analysis restricted to
use of combined oral contraceptives showed an effect for duration
of use very similar to that for all oral contraceptives. There was no
association between ever use of progestagen-only oral contra-
ceptives and risk of squamous cell or adenocarcinoma in analyses
adjusted for the duration of use of combined oral contraceptives;
these analyses are based on limited numbers. Direct comparison
showed no significant differences between squamous cell and
adenocarcinoma in relation to oral contraceptive use.
Barrier contraceptives
Information on use of barrier methods of contraception was
available only for women with regular sexual partners. Ever use of
barrier contraceptives was associated with a decreased risk of
cervical cancer, which for squamous cell carcinoma was of
marginal statistical significance (ORs for ever use compared with
never use¼0.77 (0.58–1.02) for squamous cell carcinoma and 0.87
(0.61–1.24) for adenocarcinoma). Twelve women in the study
reported using barrier methods always with all regular sexual
partners; all of these women were controls.
Smoking
The prevalence of ever smoking was 57% among control women.
Ever smoking was not associated with the risk of squamous cell
carcinoma (OR¼1.05 (0.79–1.40) or of adenocarcinoma
(OR¼0.80 (0.56–1.13)). For squamous cell carcinoma, the results
suggest that the risk of cancer was higher for current smokers
(OR¼1.26 (0.93–1.71)) than for ex-smokers (OR¼0.70 (0.47–
1.03)). The risk of squamous cell carcinoma was significantly
increased in long-term (20 or more years) smokers, with an odds
ratio of 2.05 (1.29–3.26) and a trend for duration of smoking of
borderline significance (P trend¼0.05). For adenocarcinoma, no
association was seen between cancer risk and duration of smoking.
No association was found between either type of cervical cancer
and intensity of smoking or the age at which smoking started.
Direct comparison between squamous cell carcinoma and
adenocarcinoma cases showed a consistently higher risk associated
with smoking for squamous cell carcinoma. The difference
between cancer types was statistically significant for current
smoking (OR for squamous cell compared with
adenocarcinoma¼1.74 (1.11–2.71) and for duration of smoking
(OR¼2.44 (1.26–4.72) for smoking duration of 20þ years, with a
statistically significant trend in relation to duration of smoking (P
Table 1 Odds ratios (ORs) and 95% confidence intervals (CIs) for adenocarcinomas and squamous cell carcinomas of the cervix in relation to sexual
behaviour and body weight
Adenocarcinoma Squamous cell carcinoma Squamous vs adenocarcinoma
Cases/controls ORa 95% CI Cases/controls ORb 95% CI Squamous/adeno cases ORc 95% CI
Lifetime number of sexual partners
1 52/417 1.00 60/417 1.00 60/52 1.00
2–4 84/330 1.96 1.31–2.93 186/330 3.31 2.34–4.70 186/84 1.65 1.00–2.73
5+ 44/176 1.98 1.21–3.26 145/176 4.09 2.75–6.08 145/44 1.78 1.00–3.18
Trend test P¼0.1 Po0.0001 P¼0.3
Lifetime number of regular sexual partners
(3+ months)
a
0 or 1 63/499 1.00 91/499 1.00 91/63 1.00
2 60/223 1.97 1.29–3.02 111/223 2.30 1.62–3.27 111/60 1.01 0.61–1.67
3+ 57/201 2.18 1.36–3.47 189/201 3.40 2.38–4.86 189/57 1.63 0.97–2.71
Trend P¼0.003 Po0.0001 P¼0.03
Lifetime number of nonregular sexual
partners
b
0 101/603 1.00 170/603 1.00 170/101 1.00
1–4 66/251 1.26 0.85–1.87 163/251 1.39 1.02–1.89 163/66 1.09 0.70–1.70
5+ 13/69 0.75 0.37–1.52 58/69 1.29 0.80–2.07 58/13 1.28 0.60–2.75
Trend P¼0.3 P¼0.5 P¼0.5
Age at first intercourse (years)
20+ 32/283 1.00 42/283 1.00 42/32 1.00
18–19 57/297 1.41 0.86–2.32 103/297 1.43 0.93–2.20 103/57 1.03 0.55–1.92
p17 91/343 2.01 1.23–3.30 246/343 2.70 1.78–4.11 246/91 1.38 0.75–2.55
Trend P¼0.004 Po0.0001 P¼0.2
Weight at reference age (kg)
c
o55 52/289 1.00 141/289 1.00 141/52 1.00
55–64 82/359 1.25 0.84–1.86 151/359 0.95 0.70–1.30 151/82 0.71 0.45–1.13
65+ 45/273 1.00 0.63–1.57 99/273 0.85 0.61–1.20 99/45 0.90 0.54–1.52
Trend P¼0.7 P¼0.4 P¼0.8
Body mass index at reference age
c
Normal (20–24.9) 104/540 1.00 228/540 1.00 228/104 1.00
Overweight/obese (25+) 40/219 0.98 0.64–1.49 78/219 0.87 0.62–1.23 78/40 0.89 0.55–1.46
Underweight (o20) 35/162 1.16 0.74–1.81 85/162 1.11 0.79–1.55 85/35 0.90 0.54–1.49
ORa, odds ratio for adenocarcinoma vs controls; ORb, odds ratio for squamous cell carcinoma vs controls; ORc, odds ratio for squamous cell carcinoma cases vs adenocarcinoma
cases; all adjusted for age, region, smoking, duration of oral contraceptive use, number of negative screening results and education and adjusted as appropriate for total number of
sexual partners and age at first intercourse.
aAdjusted for nonregular partners instead of total partners.
bAdjusted for regular partners instead of total partners.
cReference
age¼age 1 year before diagnosis (cases) or pseudodiagnosis (controls).
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squamous cell carcinoma and to decreased risk (with odds ratios
of around 0.8) for adenocarcinoma (Table 4).
DISCUSSION
This study was designed to provide a direct comparison of risk
factors for invasive adenocarcinoma (including adenosquamous
carcinoma) and squamous cell carcinoma of the cervix in
premenopausal women. For squamous cell carcinoma, increased
risk was associated with increased number of regular sexual
partners, early age at first intercourse, use of oral contraceptives,
high parity, early age at first birth and long-term smoking.
Adenocarcinoma risk was associated with the number of regular
sexual partners, early age at first intercourse, oral contraceptive
use and early age at first birth. No significant associations were
seen between parity or smoking and the risk of adenocarcinoma.
The difference between squamous cell and adenocarcinoma in
relation to smoking was statistically significant.
Adenocarcinomas and adenosquamous carcinomas of the cervix
account for about 15% of invasive cervical cancers, and both
absolute and relative numbers of adenocarcinomas in screened
populations have increased in recent years. This may reflect a
cohort effect similar to that seen for squamous cell carcinomas and
related to increased exposure to HPV infection in women born
since 1960 (Madeleine et al, 2001; Sasieni and Adams, 2001), and
the fact that cervical screening may be less effective in detecting
adenocarcinomas than squamous cell carcinomas (Clarke and
Anderson, 1979; Mitchell et al, 1995; Bergstrom et al, 1999). Their
relative rarity has limited attempts to define risk factors for
adenocarcinomas and adenosquamous carcinomas of the cervix
(Silcocks et al, 1987; Parazzini and La Vecchia, 1990; Kjaer and
Brinton, 1993), but several recent controlled studies with relatively
large numbers (over 100) of adenocarcinoma cases have provided
clearer evidence (Ursin et al, 1994, 1996; Bjorge and Kravdal, 1996;
Thomas and Ray, 1996; Lacey et al, 1999, 2000, 2001; Madeleine
et al, 2001; Munoz et al, 2002; Altekruse et al, 2003). Of these
studies, four (one cohort study (Bjorge and Kravdal, 1996) and
three multicentre case–control studies from WHO (WHO, 1993;
Thomas and Ray, 1995), IARC (Munoz et al, 2002) and the USA
(Lacey et al, 1999, 2000, 2001; Altekruse et al, 2003)) have directly
compared risk factors for adenocarcinoma and squamous cell
carcinoma. While many risk factors appear to be common to both
types of cervical cancer, it has been suggested that adenocarcino-
mas of the cervix may also show similarities with adenocarcinomas
of the endometrium (Kjaer and Brinton, 1993; Altekruse et al,
2003).
While there is strong evidence that HPV infection is the major
factor in the development of adenocarcinomas and adenosqua-
mous carcinomas as well as of squamous cell carcinomas of the
cervix, adenocarcinomas have been associated particularly with
HPV type 18 and related virus types, unlike squamous cell
carcinomas in which in most populations HPV 16 and related
types predominate (Clifford et al, 2003). A number of studies have
found a lower prevalence of HPV infection associated with
adenocarcinomas (70–80%) than with squamous cell carcinomas
(virtually all of which are associated with HPV using recent PCR
methods) (Andersson et al, 2001; Lo et al, 2002; Clifford et al,
2003). It is not clear whether this represents a real difference
Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for adenocarcinomas and squamous cell carcinomas of the cervix in relation to
reproductive factors
Adenocarcinoma Squamous cell carcinoma Squamous vs adenocarcinoma
Cases/controls ORa 95% CI Cases/controls ORb 95% CI Squamous/adeno cases ORc 95% CI
Ever given birth
Never 21/150 1.00 60/150 1.00 60/21 1.00
Ever 159/773 1.24 0.72–2.14 331/773 1.26 0.85–1.86 331/159 1.09 0.58–2.04
Total number of live births
0 21/150 1.00 60/150 1.00 60/21 1.00
1 38/176 1.27 0.69–2.34 62/176 0.88 0.55–1.40 62/38 0.73 0.36–1.49
2 65/377 1.14 0.63–2.05 145/377 1.41 0.92–2.17 145/65 1.33 0.67–2.63
3+ 56/220 1.44 0.76–2.73 124/220 1.86 1.16–2.99 124/56 1.47 0.70–3.11
Trend P¼0.3 P¼0.001 P¼0.1
Time since last birth
Never 21/150 1.00 60/150 1.00 60/21 1.00
p10 years 77/468 1.13 0.65–1.99 219/468 1.30 0.88–1.94 219/77 1.24 0.65–2.37
10+ years 82/305 1.63 0.86–3.07 112/305 1.07 0.66–1.73 112/82 0.66 0.32–1.40
Heterogeneity between groups
within parous women
P¼0.2 P¼0.3 P¼0.03
Age at first birth
Never 21/150 1.00 60/150 1.00 60/21 1.00
25+ years 36/272 0.92 0.49–1.70 70/272 0.94 0.60–1.47 70/36 1.07 0.52–2.18
20–24 years 63/322 1.40 0.77–2.55 108/322 1.23 0.79–1.91 108/63 1.04 0.51–2.11
15–19 years 60/179 1.71 0.89–3.29 153/179 2.01 1.26–3.21 153/60 1.16 0.57–2.38
Trend within parous women P¼0.03 P¼0.002 P¼0.7
Number of interrupted pregnancies
0 126/647 1.00 239/647 1.00 239/126 1.00
1+ 54/276 0.91 0.63–1.31 152/276 1.16 0.88–1.54 152/54 1.36 0.89–2.08
ORa, odds ratio for adenocarcinoma vs controls; ORb, odds ratio for squamous cell carcinoma vs controls; ORc, odds ratio for squamous cell carcinoma vs adenocarcinoma cases;
all adjusted for age, region, total number of sexual partners, age at first intercourse, smoking, duration of oral contraceptive use, number of negative screening results and
education.
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adenomatous tumours. Other established risk factors for cervical
cancer may affect exposure to HPV infection (e.g. number of
sexual partners) or may influence the outcome of HPV infection
(e.g. oral contraceptive use (Moreno et al, 2002; Green et al, 2003;
Smith et al, 2003), reproductive factors such as parity (Munoz et al,
2002) and possibly smoking (Plummer et al, in press)).
Sexual behaviour, and in particular the number of sexual
partners, is strongly associated both with HPV infection and with
the risk of squamous cell carcinoma of the cervix. Most controlled
studies have also found the risk of cervical adenocarcinoma to
increase directly with the lifetime number of sexual partners
(Brinton et al, 1987; Parazzini et al, 1988; Ursin et al, 1996;
Chichareon et al, 1998; Madeleine et al, 2001; Altekruse et al,
2003), and studies providing a direct comparison have found no
differences in risk between adenocarcinoma and squamous cell
carcinoma in all and in HPV-positive women (Brinton et al, 1987;
Horowitz et al, 1988; Brinton et al, 1993; Chichareon et al, 1998;
Ngelangel et al, 1998). Our results are consistent with existing
evidence. In our study the risk of both types of cervical carcinoma
was related only to the number of regular sexual partners; similar
results have also been reported in two previous studies (Brinton
et al, 1987; Herrero et al, 1990) and may reflect the need for
repeated exposure to the HPV virus for persistent infection to be
established. Early age at first intercourse, while clearly related to
lifetime number of partners, is generally considered to be an
independent risk factor for squamous cell carcinoma of the cervix
(Herrero et al, 1990; Cuzick et al, 1996; Deacon et al, 2000), and we
Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for adenocarcinomas and squamous cell carcinomas of the cervix in relation to
contraceptive use
Adenocarcinoma Squamous cell carcinoma Squamous vs adenocarcinoma
Cases/controls ORa 95% CI Cases/controls ORb 95% CI Squamous/adeno cases ORc 95% CI
Oral contraceptive (OC) use
Never
a 33/232 1.00 62/232 1.00 62/33 1.00
Ever 147/691 1.56 1.01–2.42 329/691 1.37 0.97–1.94 329/147 1.35 0.64–2.86
Past 108/543 1.42 0.91–2.23 244/543 1.31 0.92–1.87 244/108 0.97 0.56–1.66
Current 39/148 2.36 1.34–4.16 85/148 1.64 1.06–2.55 85/39 0.76 0.39–1.45
Duration of OC use
Never
a 33/232 1.00 62/232 1.00 62/33 1.00
1–5 years 41/282 1.06 0.63–1.78 97/282 1.01 0.67–1.50 97/41 0.97 0.52–1.80
5–10 years 66/277 1.90 1.16–3.11 141/277 1.55 1.05–2.29 141/66 0.78 0.43–1.41
10+ years 40/132 2.06 1.19–3.57 91/132 1.89 1.22–2.93 91/40 1.07 0.56–2.02
Trend P¼0.001 Po0.0001 P¼0.8
Time since last use of OC
Never
a 33/232 1.00 62/232 1.00 62/33 1.00
p5 years 92/383 2.14 1.31–3.50 221/383 1.62 1.11–2.35 221/92 0.86 0.48–1.52
5+ years 55/308 1.18 0.72–1.93 108/308 1.12 0.76–1.65 108/55 0.99 0.55–1.79
Heterogeneity between groups within ever users P¼0.009 P¼0.02 P¼0.8
Duration by time since last use of OC
p5 years since last use
Never
a 33/232 1.00 62/232 1.00 62/33 1.00
1–5 years 15/94 1.53 0.71–3.34 29/94 0.73 0.41–1.31 29/15 0.52 0.21–1.28
5+ years 77/289 2.18 1.28–3.73 192/289 1.66 1.11–2.48 192/77 0.88 0.47–1.66
Trend P¼0.004 P¼0.001 P¼0.8
45 years since last use
Never
a 33/232 1.00 62/232 1.00 62/33 1.00
1–5 years 26/188 1.09 0.60–1.98 68/188 1.19 0.76–1.86 68/26 1.15 0.56–2.38
5+ years 29/120 1.75 0.96–3.18 40/120 1.22 0.73–2.03 40/29 0.65 0.31–1.37
Trend P¼0.06 P¼0.5 P¼0.2
Duration of combined OC use
b
Never
a 34/237 1.00 66/237 1.00 66/34 1.00
1–5 years 42/293 1.03 0.62–1.72 102/293 0.98 0.66–1.44 102/42 0.92 0.49–1.69
5–10 years 66/279 1.81 1.11–2.95 137/279 1.35 0.92–1.98 137/66 0.71 0.40–1.29
10+ years 36/110 2.19 1.25–3.85 81/110 1.84 1.18–2.89 81/36 1.02 0.53–1.96
Trend P¼0.001 P¼0.001 P¼0.991
Ever use of progestagen-only OCs
b,c
Never
a 163/864 1.00 359/864 1.00 359/163 1.00
Ever 15/55 1.28 0.68–2.43 27/55 1.27 0.74–2.18 27/15 0.75 0.36–1.58
Use of barrier method with regular partners
d,e
Never 73/303 1.00 176/303 1.00 176/73 1.00
Ever 107/616 0.87 (0.61–1.24) 215/616 0.77 (0.58–1.02) 215/107 0.79 (0.52–1.25)
ORa, odds ratio for adenocarcinoma vs controls; ORb, odds ratio for squamous cell carcinoma vs controls; ORc, odds ratio for squamous cell carcinoma cases vs adenocarcinoma
cases; all adjusted for age, region, total number of sexual partners, age at first intercourse, smoking, number of negative screening results and education.
a‘Never’ use includes use
for less than I year.
bExcluding those who only used an unknown OC.
cAdditionally adjusted for duration of combined OC use.
dLimited to women with at least one regular
partner.
eAdditionally adjusted for duration of OC use.
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risk factor for both adenocarcinoma and squamous cell carcinoma
in the present study. Previous studies of adenocarcinoma of the
cervix have generally found no association between age at first
intercourse and cancer risk in analyses adjusted for the number of
sexual partners (Brinton et al, 1987; Brinton et al, 1993; Ursin et al,
1996; Chichareon et al, 1998; Ngelangel et al, 1998; Altekruse et al,
2003).
In this study, both high parity and early age at first birth were
associated with the risk of squamous cell carcinoma of the cervix;
adenocarcinoma risk was associated with early age at first birth but
not with parity. Munoz et al (2002), in a pooled analysis of 10
case–control studies in HPV-positive women, found that the risk
of squamous cell carcinoma increased with the number of full-
term pregnancies; there was no equivalent trend in the risk of
adenocarcinoma and adenosquamous carcinoma, although the risk
of adenocarcinoma was higher in parous women than in
nulliparous. Most other case–control studies, including those
taking HPV infection into account, have shown an association with
parity for squamous cell carcinoma of the cervix (Brinton et al,
1987, 1993; Parazzini et al, 1988; Hildesheim et al, 2001; Altekruse
et al, 2003) but, with the exception of one study (Parazzini et al,
1988), not for adenocarcinoma (Brinton et al, 1987, 1993; Ursin
et al, 1996). Altekruse et al (2003) found an inverse relationship
between parity and cervical adenocarcinoma risk. No association
with parity for either adenocarcinoma or squamous cell carcinoma
of the cervix was found in two cohort studies (Kvale et al, 1988;
Bjorge and Kravdal, 1996). Case–case studies have generally found
adenocarcinoma to be more strongly associated than squamous
cell carcinoma with nulliparity (Tasker and Collins 1974;
Korhonen, 1980; Milsom and Friberg 1983; Silcocks et al, 1987),
but these studies are difficult to interpret as most of them lack
adequate adjustment for potential confounding factors. Previous
studies of cervical cancer have found age at first birth to be an
independent risk factor for squamous cell (Munoz et al, 2002), but
not for adenocarcinoma (Kvale et al, 1988; Parazzini et al, 1988,
Bjorge and Kravdal, 1996; Ursin et al, 1996; Munoz et al, 2002;
Altekruse et al, 2003).
The use of barrier methods of contraception has been associated
with decreased risk both of preinvasive cervical lesions and of
invasive (largely squamous) cervical cancers (Manhart and
Koutsky, 2002), and this association has been found in studies
restricted to HPV-positive women (Kjaer et al, 1996, Coker et al,
2001, Hildesheim et al, 2001). The evidence, although suggestive of
a protective effect of barrier contraception, is not entirely
consistent and interpretation is severely limited in most studies
by the lack of detailed reliable evidence on contraceptive use.
There is limited evidence for a decreased risk of adenocarcinoma
associated with the use of barrier methods (Ursin et al, 1996;
Altekruse et al, 2003). Our results, adjusted for sexual behaviour
and for oral contraceptive use, are consistent with a reduced risk of
both types of cervical cancer in barrier contraceptive users. It is
interesting that all of the 12 women in this study who reported
using barrier contraceptives always with all (regular) partners were
among the controls.
Oral contraceptive use is a well-established risk factor for
cervical cancer; recent analyses of case–control and cohort studies
have confirmed that risk for both squamous cell and adenocarci-
noma is directly related to the duration of use of oral contra-
ceptives in all and in HPV-positive women, (Moreno et al, 2002;
Smith et al, 2003). The effect of oral contraceptives on cancer risk
is strongest for current and recent use and decreases with time
since last use. Our results are entirely consistent with these
previous studies and show clearly the inter-relationship between
duration of use and time since last use of oral contraceptives for
both adenocarcinoma and squamous cell carcinoma. Previously
published results from the UK National Case–Control Study of
Cervical Cancer (based on a subset of the cases and controls
included in this analysis) have shown that the association between
risk of cervical cancer and duration of use of oral contraceptives in
this study is also seen in analyses restricted to HPV-positive
women (Berrington et al, 2002). As in other studies, the majority of
Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for adenocarcinomas and squamous cell carcinomas of the cervix in relation to smoking
Adenocarcinoma Squamous cell carcinoma Squamous vs adenocarcinoma
Cases/controls ORa 95% CI Cases/controls ORb 95% CI Squamous/adeno cases ORc 95% CI
Smoking status
Never 72/394 1.00 121/394 1.00 121/72 1.00
Ever 108/529 0.80 0.56–1.13 270/529 1.05 0.79–1.40 270/108 1.50 0.99–2.27
Past 32/181 0.75 0.46–1.20 60/181 0.70 0.47–1.03 60/32 1.05 0.60–1.85
Current 76/348 0.82 0.56–1.21 210/348 1.26 0.93–1.71 210/76 1.74 1.11–2.71
Age started smoking
Never 72/394 1.00 121/394 1.00 121/72 1.00
10–16 years 60/300 0.71 0.47–1.08 165/300 1.07 0.77–1.47 165/60 1.68 1.04–2.72
17+ years 48/229 0.91 0.59–1.38 105/229 1.04 0.74–1.47 105/48 1.31 0.80–2.16
Heterogeneity between groups within ever smokers P¼0.1 P¼0.8 P¼0.06
Total duration for current smokers
Never/o1 month 72/394 1.00 121/394 1.00 121/72 1.00
p10 years 8/43 0.85 0.34–2.12 22/43 0.69 0.35–1.37 22/8 1.08 0.40–2.91
10–20 years 37/192 0.72 0.44–1.18 116/192 1.13 0.79–1.62 116/37 1.66 0.96–2.85
20+ years 31/113 0.80 0.46–1.39 72/113 2.05 1.29–3.26 72/31 2.44 1.26–4.72
Trend within current smokers P¼0.3 P¼0.05 P¼0.04
Intensity (cigarettes per day) for current smokers
Never 72/394 1.00 121/394 1.00 121/72 1.00
o15 39/194 0.72 0.45–1.15 109/194 1.28 0.90–1.82 109/39 1.92 1.13–3.25
15+ 37/154 0.82 0.51–1.34 101/154 1.26 0.86–1.83 101/37 1.68 0.97–2.92
Heterogeneity between groups within current smokers P¼0.8 P¼0.8 P¼0.9
ORa, odds ratio for adenocarcinoma vs controls; ORb, odds ratio for squamous cell carcinoma vs controls; ORc, odds ratio for squamous cell carcinoma cases vs adenocarcinoma
cases; all adjusted for age, region, total number of sexual partners, age at first intercourse, duration of oral contraceptive use, number of negative screening results and education.
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oral contraceptives and our results for ever use and for duration of
use were similar for all oral contraceptives and for combined oral
contraceptives only. We found no significant association between
the ever use of progestagen-only oral contraceptives and risk of
adenocarcinoma or squamous cell carcinoma of the cervix in
analyses adjusted for duration of oral contraceptive use. These
results are, however, based on small numbers and the ORs are not
incompatible with those for ever use of all (very largely, combined)
oral contraceptives. Use of progestagen-only injectable contra-
ceptives may be associated with a small increase in the risk of
cervical cancer (Smith et al, 2003); it is not clear whether this is
related to histology (Thomas and Ray, 1995).
We found evidence for an association between duration of
smoking and the risk of squamous cell carcinoma, but no
significant association between smoking and adenocarcinoma risk.
This is consistent with the results of previous studies (Plummer
et al, in press). No study has reported a significant association
between smoking and the risk of adenocarcinoma of the cervix
(Brinton et al, 1987; Parazzini et al, 1988; Ursin et al, 1996;
Chichareon et al, 1998; Ngelangel et al, 1998; Lacey et al, 2001;
Madeleine et al, 2001) and of four case–control studies directly
comparing risk for adenocarcinoma and squamous cell carcinoma,
smoking was found to be a significant risk factor for squamous cell
carcinoma but not for adenocarcinoma in two (Brinton et al, 1987,
Ngelangel et al, 1998), with no statistically significant association
between smoking and cervical cancer in the other two studies
(Chichareon et al, 1998; Lacey et al, 2001). In the study by Lacey
et al, the results suggested that smoking may increase the risk of
squamous cell carcinoma, but decrease the risk of adenocarcinoma
(with odds ratios for ever smoking of 1.6 (0.9–2.9) for squamous
cell carcinoma and 0.6 (0.3–1.1) for adenocarcinoma). In our
analysis, smoking was also consistently associated with an
increased risk of squamous cell carcinoma and a decreased risk
of adenocarcinoma. Further evidence is needed to clarify the
relationship between smoking and different histological types of
cervical cancer, but it appears that smoking may be a risk factor
for squamous cell and not for adenocarcinoma. A greater effect of
smoking on the risk of squamous cell carcinoma would be
consistent with the pattern of risk identified for some other types
of epithelial cancer, for example, cancers of the oesophagus, of the
nasal cavity and possibly of the lung (IARC, in press).
Other postulated risk factors for carcinomas of the cervix
include socioeconomic status and body weight. While we found no
association between educational level and either type of cancer in
the present study, there is consistent evidence from controlled
studies that the risk both of adenocarcinoma and of squamous cell
carcinoma of the cervix is higher in women of low socioeconomic
status (Parikh et al, 2003). Early reports from case–case studies
suggesting that squamous cell and adenocarcinomas differed in
relation to socioeconomic status may have been due to confound-
ing by factors such as smoking. Four out of five case–control
studies with information on body weight have reported an
increased risk of adenocarcinoma of the cervix in women with
high body mass index (Parazzini et al, 1988; Lacey et al, 2001),
weight (Brinton et al, 1987; Lacey et al, 2001) or weight gain in
adult life (Ursin 96), with no association for squamous cell
carcinoma where a direct comparison was made (Brinton et al,
1987; Lacey et al, 2001). The remaining study found no evidence of
an association between weight and risk of adenocarcinoma or
squamous cell carcinoma (Brinton et al, 1993), and no consistent
difference was found in body weight between women with
adenocarcinoma and those with squamous cell carcinoma in
case–case studies (Korhonen, 1980; Milsom and Friberg, 1983;
Honore et al, 1991; Hopkins and Morley, 1991). There was no
evidence in the present study of an association between squamous
cell or adenocarcinoma and self-reported body weight. Evidence
relating to body weight is difficult to interpret because of
limitations in the measures of weight used, and, in some studies,
in the degree of adjustment for confounding factors.
The suggestion that adenocarcinomas of the uterine cervix may
be more closely related in aetiology to adenocarcinomas of the
endometrium than to squamous cell carcinomas of the cervix was
based initially on reports from case–case and small case–control
studies. These suggested that cervical adenocarcinomas shared
many of the risk factors associated with endometrial carcinoma,
including obesity, nulliparity, diabetes, hypertension and a lack of
(or even inverse) relationship with smoking. More recent evidence
discussed here does not on the whole support this view. There is
clear evidence that strong risk factors such as HPV infection,
sexual activity and oral contraceptive use are common to both
histological types of cervical cancer (and show no or, in the case of
oral contraceptive use, an inverse relationship with endometrial
cancer); and no good evidence that squamous cell and adeno-
carcinomas of the cervix differ in relation to body weight,
socioeconomic status, diabetes or hypertension. Unlike endome-
trial cancer, neither type of cervical cancer is related to age at
menarche or age at menopause. The relationship between parity
and adenocarcinoma of the cervix is less clear than that seen for
squamous cell carcinoma, but the suggestion that adenocarcino-
mas resemble endometrial carcinomas (which show an inverse
relationship with parity) in this respect has not been confirmed.
The only consistent difference between cervical squamous cell and
adenocarcinomas appears to be in relation to smoking.
Our study has a number of limitations, many of which apply also
to other published studies. We were unable to take HPV status into
account directly in the present analyses, although adjustment for
number of sexual partners should to some extent act as a surrogate
for adjustment for HPV. We combined cases of adenocarcinoma
and of adenosquamous carcinoma in order to obtain larger
numbers of these relatively rare cancers. However, risk factors for
adenocarcinoma and adenosquamous carcinoma may differ
(Brinton et al, 1987) and ideally they should be considered
separately. There is also the possibility that some tumours may
have been misclassified. We used histological diagnoses from
medical records; in comparable studies, up to 5% of recorded
adenocarcinomas were reclassified on histological review (Lacey
et al, 1999; Madeleine et al, 2001). It has been suggested that
‘contamination’ of cervical adenocarcinomas with adenocarcino-
mas arising in the endometrium could account for differences
observed between cervical squamous cell and adenocarcinomas.
However, in this study of premenopausal women, misclassification
of endometrial adenocarcinomas is very unlikely as endometrial
cancer is predominantly a disease of postmenopausal women. It
should also be borne in mind that a substantial proportion of
women diagnosed with cervical adenocarcinoma may have
concurrent squamous cell carcinomas (Brinton et al, 1993,
Madeleine et al, 2001).
The main strengths of our study are the relatively large numbers
of women with adenocarcinoma, giving the study sufficient power
to detect equivalent risks for both types of carcinoma (the study
had 80% power at 95% significance to detect individual risk factor
ORs of between 1.5 and 2.0 for risk factor prevalences between 10
and 80%, for both squamous cell and adenocarcinoma), and the
fact that we were able to adjust for major potential confounding
factors in the analyses. This study provides information on risk
factors for cervical cancer in young women, a relatively little
studied group in whom the incidence of adenocarcinoma of the
cervix has increased in recent years. Our findings are generally
consistent with those from a previous study of squamous cell
carcinoma of the cervix in young women in the UK (Cuzick et al,
1996), in particular, in the importance of sexual behaviour as
a risk factor and in the lack of effect of socioeconomic status on
risk.
This study provides evidence to support the view that squamous
cell and adenocarcinomas of the cervix share many risk factors,
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yincluding those likely to be related to exposure to HPV infection,
such as sexual behaviour, and those, such as oral contraceptive
use, more likely to affect the outcome of HPV infection. Smoking,
however, while clearly related positively to the risk of squamous
cell carcinoma was not (or even, possibly, inversely) related to the
risk of adenocarcinoma. This finding is consistent with those from
other studies. Further information is needed to confirm these
results.
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